公开(公告)号：US11384122B2

公开(公告)日：2022-07-12

申请号：US17387105

申请日：2021-07-28

申请人： Janssen Pharmaceuticals, Inc. ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Johannes Petrus Maria Langedijk ,  Lucy Rutten ,  Mark Johannes Gerardus Bakkers ,  Rinke Bos ,  Frank Wegmann ,  David Adrianus Theodorus Maria Zuijdgeest ,  Dan H. Barouch ,  An Vandebosch ,  Mathieu Claude Michel le Gars ,  Jerald C. Sadoff

IPC分类号： A61K39/00 ,  C07K14/005 ,  A61K35/12 ,  A61K39/08 ,  A61K39/12 ,  A61P31/14 ,  C12N7/00 ,  C12N15/86 ,  A61K39/215

摘要： The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.

公开(公告)号：US20210317192A9

公开(公告)日：2021-10-14

申请号：US16887710

申请日：2020-05-29

申请人： Massachusetts Institute of Technology ,  The General Hospital Corporation ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Darrell J. Irvine ,  Dan H. Barouch ,  Arup K. Chakraborty ,  Dariusz Murakowski ,  Bruce D. Walker ,  John Barton ,  Andrew Ferguson

IPC分类号： C07K16/10 ,  A61K39/12 ,  A61P31/14 ,  C12N15/86

摘要： Disclosed herein are methods and compositions for treating a subject having or at risk of having an HIV infection. Disclosed herein are peptide immunogens and nucleic acids that have epitopes in which mutations are most likely to have deleterious effects on the HIV virus. An algorithm is disclosed for the selection of the epitopes based on the HIV fitness landscape, and it accounts for the effect of coupling mutations.

公开(公告)号：US10716845B2

公开(公告)日：2020-07-21

申请号：US15026391

申请日：2014-10-03

申请人： Beth Israel Deaconess Medical Center, Inc.

发明人： Dan H. Barouch ,  Christine Bricault

IPC分类号： A61K39/12 ,  A61K39/21 ,  C07K14/16 ,  C12N7/00 ,  A61K39/00

摘要： The invention features stabilized human immunodeficiency virus (H IV) clade C envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV clade C Env trimers. In addition, the invention features methods of making and using the stabilized HIV clade C Env trimers of the invention.

公开(公告)号：US20160024156A1

公开(公告)日：2016-01-28

申请号：US14632869

申请日：2015-02-26

申请人： Beth Israel Deaconess Medical Center, Inc. ,  Los Alamos National Security, LLC

发明人： Dan H. Barouch ,  Bette T. Korber ,  William M. Fischer

IPC分类号： C07K14/005 ,  A61K39/235 ,  A61K39/275 ,  C12N7/00

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K39/235 ,  A61K39/275 ,  A61K2039/53 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/10043 ,  C12N2710/10343 ,  C12N2710/24043 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2740/16322 ,  C12N2740/16334 ,  Y02A50/467

摘要： The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.

摘要翻译： 本发明提供用于治疗或预防病毒感染的组合物，方法和试剂盒。 本文所述的多价（例如2价）疫苗引入计算优化的病毒多肽，其可以增加接种受试者的细胞免疫应答的多样性或广度和深度。

公开(公告)号：US11202830B2

公开(公告)日：2021-12-21

申请号：US16535921

申请日：2019-08-08

申请人： Beth Israel Deaconess Medical Center, Inc.

发明人： Dan H. Barouch

IPC分类号： A61K39/42 ,  C07K16/10 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06

摘要： Described are N332 glycan-dependent antibodies for treating human immunodeficiency virus (HIV) in a subject that is infected with HIV and that is receiving antiretroviral therapy (ART).

公开(公告)号：US10463729B2

公开(公告)日：2019-11-05

申请号：US16385438

申请日：2019-04-16

申请人： Beth Israel Deaconess Medical Center, Inc. ,  Children's Medical Center Corporation

发明人： Stephen C. Harrison ,  Bing Chen ,  Dan H. Barouch ,  Joseph P. Nkolola ,  Michael Scott Seaman

IPC分类号： A61K39/21 ,  C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  C12N7/00

摘要： Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.

公开(公告)号：US10426831B2

公开(公告)日：2019-10-01

申请号：US15489220

申请日：2017-04-17

申请人： Beth Israel Deaconess Medical Center, Inc. ,  Triad National Security, LLC

发明人： Dan H. Barouch ,  Bette T. Korber ,  William M. Fischer

IPC分类号： A61K39/21 ,  C07K14/005 ,  A61K39/12 ,  A61K39/235 ,  A61K39/275 ,  C12N7/00 ,  A61K39/00

摘要： The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.

公开(公告)号：US10376583B2

公开(公告)日：2019-08-13

申请号：US15025961

申请日：2014-09-30

申请人： Beth Israel Deaconess Medical Center, Inc.

发明人： Dan H. Barouch

IPC分类号： A61K39/42 ,  C07K16/10 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

摘要： This invention relates to antibody therapies for human immunodeficiency virus (HIV). In particular, the invention provides methods of curing subjects infected with HIV and blocking HIV infections in subjects at risk of HIV transmission using a N332 glycan-dependent antibody (e.g., PGT121).

公开(公告)号：US20150291935A1

公开(公告)日：2015-10-15

申请号：US14443299

申请日：2013-11-15

申请人： BETH ISRAEL DEACONESS MEDICAL CENTER INC. ,  WASHINGTON UNIVERSITY

发明人： Dan H. Barouch ,  Herbert Virgin, IV ,  Peter Abbink

IPC分类号： C12N7/00 ,  A61K39/00

CPC分类号： C12N7/00 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/5256 ,  A61K2039/5258 ,  C12N2710/10042 ,  C12N2710/10321 ,  C12N2710/10343 ,  C12N2740/15034

摘要： The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).

摘要翻译： 本发明涉及重组腺病毒及其载体。 特别地，腺病毒是相对于其他腺病毒及其载体具有低血清阳性率和高免疫原性的新型猿猴腺病毒。 本发明还提供了通过向受试者（例如人）施用腺病毒载体来产生腺病毒和用于治疗疾病的方法。

公开(公告)号：US11773142B2

公开(公告)日：2023-10-03

申请号：US16772045

申请日：2018-12-11

申请人： Beth Israel Deaconess Medical Center, Inc.

发明人： Dan H. Barouch ,  Peter Abbink ,  Mark Justin Iampietro ,  Menzo J. E. Havenga

IPC分类号： C07K14/075 ,  A61K35/761 ,  A61K39/235 ,  A61K31/7088 ,  C07K14/54 ,  C12N15/861

CPC分类号： C07K14/075 ,  A61K31/7088 ,  A61K35/761 ,  A61K39/235 ,  C07K14/5425 ,  C12N15/861

摘要： Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).